<code id='EC562CE383'></code><style id='EC562CE383'></style>
    • <acronym id='EC562CE383'></acronym>
      <center id='EC562CE383'><center id='EC562CE383'><tfoot id='EC562CE383'></tfoot></center><abbr id='EC562CE383'><dir id='EC562CE383'><tfoot id='EC562CE383'></tfoot><noframes id='EC562CE383'>

    • <optgroup id='EC562CE383'><strike id='EC562CE383'><sup id='EC562CE383'></sup></strike><code id='EC562CE383'></code></optgroup>
        1. <b id='EC562CE383'><label id='EC562CE383'><select id='EC562CE383'><dt id='EC562CE383'><span id='EC562CE383'></span></dt></select></label></b><u id='EC562CE383'></u>
          <i id='EC562CE383'><strike id='EC562CE383'><tt id='EC562CE383'><pre id='EC562CE383'></pre></tt></strike></i>

          knowledge

          knowledge

          author:comprehensive    Page View:5387
          Two business miniatures talk to each other on coin stacks that are sandwiched by a syringe and a stethoscope — coverage from STAT
          Adobe

          For all the flak they get, the country’s four biggest pharmacy benefit managers reported a surprisingly tame average profit margin in the first three quarters of 2023: 4.5%, less than a third of their drugmaker peers.

          But don’t take their numbers as gospel, experts warned.

          advertisement

          “It’s really easy to move money around inside the books of a vertically integrated organization,” said Karen Van Nuys, a senior fellow at the USC Schaeffer Center for Health Policy and Economics. “If one segment of your vertically integrated organization is not publishing any financial data, it’s a good place to hide stuff.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Jerome Adams on the need for new antivirals for Covid
          Jerome Adams on the need for new antivirals for Covid

          PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

          read more
          FDA official pushes for dedicated emerging pathogens team
          FDA official pushes for dedicated emerging pathogens team

          PeterMarks,directoroftheFDA'sCenterforBiologicsEvaluationandResearchGregNash/PoolviaAPWASHINGTON—Ato

          read more
          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more

          Pioneering cancer drug will cost $475,000. Analysts call it a bargain

          VictorSeguraIbarraandRitaSerda,Ph.D.,NCI,NIHTheFoodandDrugAdministrationonWednesdayapprovedafuturist